Zealand Pharma — November 2023

[ProinvestorNEWS]

Jefferies London Healthcare Conference

Tuesday, November 14 at 1:30 p.m. GMT (2:30 p.m. CET)
Fireside chat with Adam Steensberg, President and Chief Executive Officer

A webcast of the fireside chat will be available on the Events page in the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/events/. A replay of the webcast will be archived on the company's website following the fireside chat.

[EliotSpitzer]

Fint at Steensberg holder gang i ilden med en fireside chat i bedste Roosevelt stil. Han plejer at være ganske god til den slags præsentationer.

[EliotSpitzer]

Aggregerede korte nettopositioner er i følge Finanstilsynet faldet til 4.03%.

[Svingtraderen]

Ser ud til at kæberbe blev vækket igen på 280-285

[Svingtraderen]

køberne...sorry

[YPE]

Positivt at shortandel er faldet til 4,03%.

[YPE]

Jeg er meget spændt til på torsdag. Har på fornemmelsen, at ZP kommer med mere end bare "regnskab". Det har de for vane at gøre, selvom de ikke må putte med noget. Vi må se..

[exitnu]

Tja, nu må vi se, måske endda rigtigt godt!

[exitnu]

Luk i kurs 290,00 & +1,40%

[exitnu]

God morgen

[Helge_LarsenPI-redaktør]

Godmorgen

[exitnu]

Klar til en god Zealand Pharma dag

[ProinvestorNEWS]

Dagens mange regnskaber: https://www.proinvestor.com/finanskalender

[Stroka]

God morgen

[ProinvestorNEWS]

Lilly : FDA Approves Zepbound For Chronic Weight Management, New Option For Treatment Of Obesity https://www.proinvestor.com/investornyt/1076597/lilly-fda-approves-zepbound-for-chronic-weight-management-new-option-for-treatment-of-obesity

[B.Andersen]

Godmorgen til en spændende Zeal-dag.

[ProinvestorNEWS]

ZEAL - Financial Results for the First Nine Mont of 2023 https://www.proinvestor.com/boards/116627

[LP90]

Godmorgen

[ProinvestorNEWS]

"Financial

Solid financial position. * Milestone payments from existing partnerships were recognized in the third quarter of 2023, with cash inflow expected in the fourth quarter of 2023, contributing to the company's solid financial position. These potential milestones include EUR 30 million from Boehringer Ingelheim associated with survodutide and USD 10 million from Sanofi associated with lixisenatide".

[exitnu]

"Finally, we will end this transformative year with a planned NDA submission for glepaglutide in short bowel syndrome and the first PDUFA date for dasiglucagon in congenital hyperinsulinism.”